Palmer D D, Henter I D, Wyatt R J
Neuropsychiatry Branch, Department of Health and Human Services, NIH-NIMH, Neuroscience Research Center at St. Elizabeths, Washington, DC 20032, USA.
J Clin Psychiatry. 1999;60 Suppl 2:100-3; discussion 111-6.
The lifetime risk of suicide in persons with schizophrenia is much greater than that in the general population. The role of antipsychotic medications in decreasing suicide risk in schizophrenia has been little studied, and results often appear inconclusive and even confusing when issues such as dose-response effect are examined. Yet, evidence exists that both the traditional and newer antipsychotic medications reduce the risk of suicide and suicide attempts in schizophrenia. Because side effects are potentially significant risk factors in suicide, considerable incentive exists to examine whether newer antipsychotic agents that have a lower incidence of extrapyramidal side effects offer greater safety for this population.
精神分裂症患者的终身自杀风险远高于普通人群。抗精神病药物在降低精神分裂症患者自杀风险方面的作用鲜少得到研究，而且在研究诸如剂量反应效应等问题时，结果往往不明确甚至令人困惑。然而，有证据表明，传统和新型抗精神病药物均可降低精神分裂症患者的自杀及自杀未遂风险。由于副作用可能是自杀的重要风险因素，因此人们有很大的动力去研究锥体外系副作用发生率较低的新型抗精神病药物是否能为该人群提供更高的安全性。
